newsfilter
← Latest News
PR Newswire·

Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

MIRAGE phase III randomized controlled trial shows a significant reduction in GU and GI toxicities with MRIdian® MRI-guided versus CT-guided SBRT DENVER, Jan. 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY)